Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Benefits from the Early Initiation of Macitentan for Pulmonary Arterial Hypertension

  • Jung, Hae Ok (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea College of Medicine)
  • Received : 2018.05.08
  • Accepted : 2018.05.31
  • Published : 2018.09.30
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013;62:D42-50. https://doi.org/10.1016/j.jacc.2013.10.032
  2. Chung WJ, Park YB, Jeon CH, et al. Baseline characteristics of the Korean Registry of Pulmonary Arterial Hypertension. J Korean Med Sci 2015;30:1429-38. https://doi.org/10.3346/jkms.2015.30.10.1429
  3. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36. https://doi.org/10.1056/NEJMra040291
  4. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012;142:448-56. https://doi.org/10.1378/chest.11-1460
  5. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156-63. https://doi.org/10.1161/CIRCULATIONAHA.109.911818
  6. Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008;327:736-45. https://doi.org/10.1124/jpet.108.142976
  7. Raja SG. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Curr Opin Investig Drugs 2010;11:1066-73.
  8. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369:809-18. https://doi.org/10.1056/NEJMoa1213917
  9. Kim KH, Kim HK, Kim YJ, Chan SY, Sohn DW. Hemodynamic and histopathologic benefits of early treatment with macitentan in a rat model of pulmonary arterial hypertension. Korean Circ J 2018;48:839-53. https://doi.org/10.4070/kcj.2017.0394
  10. Kim KC, Lee JC, Lee H, Cho MS, Choi SJ, Hong YM. Changes in caspase-3, B cell leukemia/lymphoma-2, interleukin-6, tumor necrosis factor-$\alpha$ and vascular endothelial growth factor gene expression after human umbilical cord blood derived mesenchymal stem cells transfusion in pulmonary hypertension rat models. Korean Circ J 2016;46:79-92. https://doi.org/10.4070/kcj.2016.46.1.79